Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)
Status:
Terminated
Trial end date:
2017-02-21
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if lenalidomide can increase the level
of immunoglobulins (parts of the blood that may help to improve the immune system's function)
and/or will improve the protective effect of the flu and pneumonia vaccines in patients with
CLL.